APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetes Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diabetes Screening Market Outlook and Growth Opportunities 2026

3 March 2026191 pages

Choose your research edition.

Industry ResearchDiabetes Screening Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetes Screening Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Diabetes Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetes Screening Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetes Screening Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Diabetes Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diabetes Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetes Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetes Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diabetes Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diabetes Screening market include InSphero AG, Abbott Laboratories, American Laboratory Products Company (ALPCO), Beckmann Coulter Inc., Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics Inc., F. Hoffmann-la Roche Ltd, Siemens AG and PTS Diagnostics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Diabetes Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetes Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetes Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Diabetes Screening market.

Diabetes Screening Segment by Company

InSphero AG

Abbott Laboratories

American Laboratory Products Company (ALPCO)

Beckmann Coulter Inc.

Bio-Rad Laboratories Inc.

Ortho Clinical Diagnostics Inc.

F. Hoffmann-la Roche Ltd

Siemens AG

PTS Diagnostics

Diabetes Screening Segment by Type

Instrument

Test Suite

Reagents

Diabetes Screening Segment by Application

Hospital

Specialty Clinic

Diagnostic Center

Home Care

Academic Research Institution

Diabetes Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diabetes Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Diabetes Screening key companies, revenue, market share, and recent developments.

3. To split the Diabetes Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Diabetes Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diabetes Screening significant trends, drivers, influence factors in global and regions.

6. To analyze Diabetes Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetes Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diabetes Screening industry.

Chapter 3: Detailed analysis of Diabetes Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Diabetes Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Diabetes Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diabetes Screening Industry Trends Table 2. Diabetes Screening Industry Drivers Table 3. Diabetes Screening Industry Opportunities and Challenges Table 4. Diabetes Screening Industry Restraints Table 5. Global Diabetes Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diabetes Screening Revenue Share by Company (2021-2026) Table 7. Global Diabetes Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Diabetes Screening Key Company Manufacturing Base & Headquarters Table 9. Global Diabetes Screening Company, Product Type & Application Table 10. Global Diabetes Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Diabetes Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Instrument Table 15. Significant Companies of Test Suite Table 16. Significant Companies of Reagents Table 17. Global Diabetes Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Diabetes Screening Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Diabetes Screening Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Diabetes Screening Sales Value Share by Type (2021-2026) Table 21. Global Diabetes Screening Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Specialty Clinic Table 24. Significant Companies of Diagnostic Center Table 25. Significant Companies of Home Care Table 26. Significant Companies of Academic Research Institution Table 27. Global Diabetes Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Diabetes Screening Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Diabetes Screening Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Diabetes Screening Sales Value Share by Application (2021-2026) Table 31. Global Diabetes Screening Sales Value Share by Application (2027-2032) Table 32. Global Diabetes Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Diabetes Screening Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Diabetes Screening Sales Value Share by Region (2021-2026) Table 35. Global Diabetes Screening Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Diabetes Screening Sales Value Share by Region (2027-2032) Table 37. Global Diabetes Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Diabetes Screening Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Diabetes Screening Sales Value Market Share by Country (2021-2026) Table 40. Global Diabetes Screening Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Diabetes Screening Sales Value Market Share by Country (2027-2032) Table 42. InSphero AG Company Information Table 43. InSphero AG Business Overview Table 44. InSphero AG Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. InSphero AG Diabetes Screening Product Portfolio Table 46. InSphero AG Recent Development Table 47. Abbott Laboratories Company Information Table 48. Abbott Laboratories Business Overview Table 49. Abbott Laboratories Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Abbott Laboratories Diabetes Screening Product Portfolio Table 51. Abbott Laboratories Recent Development Table 52. American Laboratory Products Company (ALPCO) Company Information Table 53. American Laboratory Products Company (ALPCO) Business Overview Table 54. American Laboratory Products Company (ALPCO) Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. American Laboratory Products Company (ALPCO) Diabetes Screening Product Portfolio Table 56. American Laboratory Products Company (ALPCO) Recent Development Table 57. Beckmann Coulter Inc. Company Information Table 58. Beckmann Coulter Inc. Business Overview Table 59. Beckmann Coulter Inc. Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Beckmann Coulter Inc. Diabetes Screening Product Portfolio Table 61. Beckmann Coulter Inc. Recent Development Table 62. Bio-Rad Laboratories Inc. Company Information Table 63. Bio-Rad Laboratories Inc. Business Overview Table 64. Bio-Rad Laboratories Inc. Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Bio-Rad Laboratories Inc. Diabetes Screening Product Portfolio Table 66. Bio-Rad Laboratories Inc. Recent Development Table 67. Ortho Clinical Diagnostics Inc. Company Information Table 68. Ortho Clinical Diagnostics Inc. Business Overview Table 69. Ortho Clinical Diagnostics Inc. Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Ortho Clinical Diagnostics Inc. Diabetes Screening Product Portfolio Table 71. Ortho Clinical Diagnostics Inc. Recent Development Table 72. F. Hoffmann-la Roche Ltd Company Information Table 73. F. Hoffmann-la Roche Ltd Business Overview Table 74. F. Hoffmann-la Roche Ltd Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. F. Hoffmann-la Roche Ltd Diabetes Screening Product Portfolio Table 76. F. Hoffmann-la Roche Ltd Recent Development Table 77. Siemens AG Company Information Table 78. Siemens AG Business Overview Table 79. Siemens AG Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Siemens AG Diabetes Screening Product Portfolio Table 81. Siemens AG Recent Development Table 82. PTS Diagnostics Company Information Table 83. PTS Diagnostics Business Overview Table 84. PTS Diagnostics Diabetes Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. PTS Diagnostics Diabetes Screening Product Portfolio Table 86. PTS Diagnostics Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Diabetes Screening Product Image Figure 2. Global Diabetes Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetes Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetes Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Instrument Image Figure 8. Test Suite Image Figure 9. Reagents Image Figure 10. Global Diabetes Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Diabetes Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Diabetes Screening Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Specialty Clinic Image Figure 15. Diagnostic Center Image Figure 16. Home Care Image Figure 17. Academic Research Institution Image Figure 18. Global Diabetes Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Diabetes Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Diabetes Screening Sales Value Share by Application (2021-2032) Figure 21. Global Diabetes Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Diabetes Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Diabetes Screening Sales Value (2021-2032) & (US$ Million) Figure 24. North America Diabetes Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Diabetes Screening Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Diabetes Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Diabetes Screening Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Diabetes Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Diabetes Screening Sales Value (2021-2032) & (US$ Million) Figure 30. South America Diabetes Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Diabetes Screening Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Diabetes Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Diabetes Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Diabetes Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Diabetes Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Instrument
  • Test Suite
  • Reagents
Applications
  • Hospital
  • Specialty Clinic
  • Diagnostic Center
  • Home Care
  • Academic Research Institution
Companies covered
  • InSphero AG
  • Abbott Laboratories
  • American Laboratory Products Company (ALPCO)
  • Beckmann Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • Ortho Clinical Diagnostics Inc.
  • F. Hoffmann-la Roche Ltd
  • Siemens AG
  • PTS Diagnostics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diabetes Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diabetes Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Diabetes Screening Market Dynamics
  1. 2.1 Diabetes Screening Industry Trends
  2. 2.2 Diabetes Screening Industry Drivers
  3. 2.3 Diabetes Screening Industry Opportunities and Challenges
  4. 2.4 Diabetes Screening Industry Restraints
3 Diabetes Screening Market by Company
  1. 3.1 Global Diabetes Screening Company Revenue Ranking in 2025
  2. 3.2 Global Diabetes Screening Revenue by Company (2021-2026)
  3. 3.3 Global Diabetes Screening Company Ranking (2024-2026)
  4. 3.4 Global Diabetes Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global Diabetes Screening Company Product Type and Application
  6. 3.6 Global Diabetes Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Diabetes Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Diabetes Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Diabetes Screening Market by Type
  1. 4.1 Diabetes Screening Type Introduction
  2. 4.1.1 Instrument
  3. 4.1.2 Test Suite
  4. 4.1.3 Reagents
  5. 4.2 Global Diabetes Screening Sales Value by Type
  6. 4.2.1 Global Diabetes Screening Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Diabetes Screening Sales Value by Type (2021-2032)
  8. 4.2.3 Global Diabetes Screening Sales Value Share by Type (2021-2032)
5 Diabetes Screening Market by Application
  1. 5.1 Diabetes Screening Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialty Clinic
  4. 5.1.3 Diagnostic Center
  5. 5.1.4 Home Care
  6. 5.1.5 Academic Research Institution
  7. 5.2 Global Diabetes Screening Sales Value by Application
  8. 5.2.1 Global Diabetes Screening Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Diabetes Screening Sales Value by Application (2021-2032)
  10. 5.2.3 Global Diabetes Screening Sales Value Share by Application (2021-2032)
6 Diabetes Screening Regional Value Analysis
  1. 6.1 Global Diabetes Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetes Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global Diabetes Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global Diabetes Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diabetes Screening Sales Value (2021-2032)
  7. 6.3.2 North America Diabetes Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Diabetes Screening Sales Value (2021-2032)
  10. 6.4.2 Europe Diabetes Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Diabetes Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Diabetes Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Diabetes Screening Sales Value (2021-2032)
  16. 6.6.2 South America Diabetes Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Diabetes Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Diabetes Screening Sales Value Share by Country, 2025 VS 2032
7 Diabetes Screening Country-level Value Analysis
  1. 7.1 Global Diabetes Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diabetes Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global Diabetes Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global Diabetes Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Diabetes Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Diabetes Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Diabetes Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Diabetes Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Diabetes Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Diabetes Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Diabetes Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Diabetes Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Diabetes Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Diabetes Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Diabetes Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Diabetes Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Diabetes Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Diabetes Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Diabetes Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Diabetes Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Diabetes Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Diabetes Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Diabetes Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Diabetes Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Diabetes Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Diabetes Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Diabetes Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Diabetes Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Diabetes Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Diabetes Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Diabetes Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Diabetes Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Diabetes Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Diabetes Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Diabetes Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 InSphero AG
  2. 8.1.1 InSphero AG Company Information
  3. 8.1.2 InSphero AG Business Overview
  4. 8.1.3 InSphero AG Diabetes Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 InSphero AG Diabetes Screening Product Portfolio
  6. 8.1.5 InSphero AG Recent Developments
  7. 8.2 Abbott Laboratories
  8. 8.2.1 Abbott Laboratories Company Information
  9. 8.2.2 Abbott Laboratories Business Overview
  10. 8.2.3 Abbott Laboratories Diabetes Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Laboratories Diabetes Screening Product Portfolio
  12. 8.2.5 Abbott Laboratories Recent Developments
  13. 8.3 American Laboratory Products Company (ALPCO)
  14. 8.3.1 American Laboratory Products Company (ALPCO) Company Information
  15. 8.3.2 American Laboratory Products Company (ALPCO) Business Overview
  16. 8.3.3 American Laboratory Products Company (ALPCO) Diabetes Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 American Laboratory Products Company (ALPCO) Diabetes Screening Product Portfolio
  18. 8.3.5 American Laboratory Products Company (ALPCO) Recent Developments
  19. 8.4 Beckmann Coulter Inc.
  20. 8.4.1 Beckmann Coulter Inc. Company Information
  21. 8.4.2 Beckmann Coulter Inc. Business Overview
  22. 8.4.3 Beckmann Coulter Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beckmann Coulter Inc. Diabetes Screening Product Portfolio
  24. 8.4.5 Beckmann Coulter Inc. Recent Developments
  25. 8.5 Bio-Rad Laboratories Inc.
  26. 8.5.1 Bio-Rad Laboratories Inc. Company Information
  27. 8.5.2 Bio-Rad Laboratories Inc. Business Overview
  28. 8.5.3 Bio-Rad Laboratories Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-Rad Laboratories Inc. Diabetes Screening Product Portfolio
  30. 8.5.5 Bio-Rad Laboratories Inc. Recent Developments
  31. 8.6 Ortho Clinical Diagnostics Inc.
  32. 8.6.1 Ortho Clinical Diagnostics Inc. Company Information
  33. 8.6.2 Ortho Clinical Diagnostics Inc. Business Overview
  34. 8.6.3 Ortho Clinical Diagnostics Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ortho Clinical Diagnostics Inc. Diabetes Screening Product Portfolio
  36. 8.6.5 Ortho Clinical Diagnostics Inc. Recent Developments
  37. 8.7 F. Hoffmann-la Roche Ltd
  38. 8.7.1 F. Hoffmann-la Roche Ltd Company Information
  39. 8.7.2 F. Hoffmann-la Roche Ltd Business Overview
  40. 8.7.3 F. Hoffmann-la Roche Ltd Diabetes Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-la Roche Ltd Diabetes Screening Product Portfolio
  42. 8.7.5 F. Hoffmann-la Roche Ltd Recent Developments
  43. 8.8 Siemens AG
  44. 8.8.1 Siemens AG Company Information
  45. 8.8.2 Siemens AG Business Overview
  46. 8.8.3 Siemens AG Diabetes Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Siemens AG Diabetes Screening Product Portfolio
  48. 8.8.5 Siemens AG Recent Developments
  49. 8.9 PTS Diagnostics
  50. 8.9.1 PTS Diagnostics Company Information
  51. 8.9.2 PTS Diagnostics Business Overview
  52. 8.9.3 PTS Diagnostics Diabetes Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 PTS Diagnostics Diabetes Screening Product Portfolio
  54. 8.9.5 PTS Diagnostics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst